Table 2. Comparison of baseline features between CD8 and PD-L1 subgroups.
| Parameters | CD8 TIL | PD-L1 expression | CD8-PDL1 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low (n=51) | High (n=43) | P | Low (n=47) | High (n=47) | P | Strong (n=24) | Mild (n=42) | Weak (n=28) | P | |||
| Sex | 0.364 | 0.834 | 0.127 | |||||||||
| Female | 19 (37.3) | 20 (46.5) | 20 (42.6) | 19 (40.4) | 9 (37.5) | 22 (52.4) | 8 (28.6) | |||||
| Male | 32 (62.7) | 23 (53.5) | 27 (57.4) | 28 (59.6) | 15 (62.5) | 20 (47.6) | 20 (71.4) | |||||
| Primary site | 0.084 | 0.778 | 0.644 | |||||||||
| Left colon | 12 (23.5) | 13 (30.2) | 11 (23.4) | 14 (29.8) | 7 (29.2) | 10 (23.8) | 8 (28.6) | |||||
| Right colon | 16 (31.4) | 20 (46.5) | 19 (40.4) | 17 (36.2) | 11 (45.8) | 17 (40.5) | 8 (28.6) | |||||
| Rectum | 23 (45.1) | 10 (23.3) | 17 (36.2) | 16 (34.0) | 6 (25.0) | 15 (35.7) | 12 (42.9) | |||||
| N stage* | 0.887 | 0.269 | 0.642 | |||||||||
| Negative | 16 (38.1) | 15 (36.6) | 17 (43.6) | 14 (31.8) | 10 (45.5) | 12 (33.3) | 9 (36.0) | |||||
| Positive | 26 (61.9) | 26 (63.4) | 22 (56.4) | 30 (68.2) | 12 (54.5) | 24 (66.7) | 16 (64.0) | |||||
| Time of metastasis | 0.002 | 0.037 | 0.528 | |||||||||
| Metachronous | 29 (56.9) | 11 (25.6) | 25 (53.2) | 15 (31.9) | 8 (33.3) | 20 (47.6) | 12 (42.9) | |||||
| Synchronous | 22 (43.1) | 32 (74.4) | 22 (46.8) | 32 (68.1) | 16 (66.7) | 22 (52.4) | 16 (57.1) | |||||
| CEA** | 0.286 | 0.764 | 0.457 | |||||||||
| >5 | 32 (68.1) | 24 (57.1) | 27 (61.4) | 29 (64.4) | 11 (47.8) | 13 (32.5) | 9 (34.6) | |||||
| ≤5 | 15 (31.9) | 18 (42.9) | 17 (38.6) | 16 (35.6) | 12 (52.2) | 27 (67.5) | 17 (65.4) | |||||
| Size of metastasis | 0.347 | 0.344 | 0.337 | |||||||||
| >3 | 15 (29.4) | 9 (20.9) | 10 (21.3) | 14 (29.8) | 5 (20.8) | 9 (21.4) | 10 (35.7) | |||||
| ≤3 | 36 (70.6) | 34 (79.1) | 37 (78.7) | 33 (70.2) | 19 (79.2) | 33 (78.6) | 18 (64.3) | |||||
*, available for 83 patients; **, available for 89 patients. CEA, carcinoembryonic antigen; TIL, tumor infiltrating lymphocytes; CD8-PDL1, combination of CD8 TIL and PD-L1 expression.